Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
Eli Lilly reported $19.3 billion in revenue for Q4 and is expanding its GLP-1 franchise into immunology and inflammation. Ongoing trials target asthma, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.